DESCRIPTION Xtra-Cell™ Comitris™
is an innovative marine liquid cartilage extract (LCE) containing
water-soluble proteins and peptides designed to help maintain healthy angiogenic balance as well as healthy hematocrit and red blood cell levels.*
FUNCTIONS
Xtra-Cell Comitris is manufactured and purified via a patented†
low temperature extraction and molecular ultrafiltration of shark cartilage
that does not involve the use of excipients, chemicals, enzymes or
preservatives. This extraction process allows for the selection of
molecules based on their size and weight, and results in a finished extract
that is composed of proteins, peptides and other compounds having
approximate molecular weights of less than 500 kilodaltons (kDa).
After extraction, the liquid is aseptically bottled and immediately
flash-frozen to preserve the structure and function of its components. Each
batch is tested for potency and purity according to validated methods.
Bioavailability of the extract has been assessed by a human clinical trial.
Xtra-Cell Comitris does not have any unpleasant odor or taste.
Angiogenesis is a natural process by which new blood vessels are formed and
grow to supply oxygen and nutrients to cells.
Angiogenesis is a complex process that is regulated at the cellular level
with a balance between factors that are proangiogenic and factors that are
anti-angiogenic. Disturbances in this balance can affect the health of
a tissue. Maintaining the integrity of the extracellular matrix (a
meshwork of protein fibers such as collagen and elastin, plus
polysaccharides including chondroitin sulfate and hyaluronic acid) is
critical for allowing the transportation of nutrients, and for providing
structure to cartilage, muscles sheaths, skin, and tendons. The normal
breakdown and regeneration of the extracellular matrix is required for
proper tissue health. However, excessive breakdown can lead to
deterioration of the matrix. Liquid cartilage extract may help to
maintain the structure and function of the extracellular matrix as well as
blood vessels and tissues by supporting the proper activity of a family of
zinc-dependent enzymes known as matrix metalloproteinases (MMPs).*
Specifically, MMP-2 MMP-9, and MMP-12 (also know as gelatinase A gelatinase
B, and metalloelastase, respectively) have been shown to be involved in both
the breakdown of the extracellular matrix as well as the breakdown of
vascular basement membranes. An imbalance in MMP activity can alter
angiogenic balance. The effect of LCE on MMP activity has been
investigated.
Figures 1 and 2 show that LCE can support healthy MMP activity.
Cytokines including IL-1 and TNF-a also promote the expression of MMPs. Liquid cartilage extract has
been shown to maintain healthy levels of IL-1 and TNF-a
which can further support healthy angiogenic balance and promote normal
inflammatory mechanisms.*
Another molecule that plays a central role in maintaining angiogenic
balance is a compound called vascular endothelial growth factor (VEGF).
When bound to one of its two receptors, VEGF can stimulate endothelial cell
proliferation, affect cell permeability, and contribute to the formation of
new blood vessels.
In a competitive binding assay, LCE has been shown to decrease the binding
of VEGF to its receptor (Figure 3).
LCE has also been shown to maintain a healthy level of VEGF-dependent
endothelial cell proliferation.* Together, the actions of LCE on MMP
activity and VEGF binding can work in concert to maintain healthy angiogenic
processes.
A more recently observed
characteristic of LCE is its ability to support healthy blood parameters.
In a randomized, double-blind, placebo controlled trial,
healthy subjects who consumed liquid cartilage extract displayed increased
mean erythrocyte count, hematocrit, and hemoglobin levels after 11 days of
supplementation.
This increase in blood parameters lasted through the 23 day duration of the study (figures 4, 5
and 6).
Increases in erythrocyte count, hematocrit and hemoglobin levels have also
been observed in a study in which cancer patients were supplemented with
LCE.
INDICATIONS Xtra-Cell Comitris may be a useful
dietary supplement for those who wish to support healthy angiogenic balance.
Comitris may also be useful to help support healthy hematocrit and red blood
cell count.
FORMULA Serving Size: 1 Bottle of 7.5 mL
Servings Per
Package: 15
Each Bottle Contains: Marine Liquid Cartilage Extract (LCE)
(fish)
...................................................................... 7.5
mL
SUGGESTED USE
As a dietary supplement, take one bottle of Xtra-Cell Comitris daily.
Take on an empty stomach either a half hour before or two hours after a
meal.
DIRECTIONS FOR USE Unscrew the cap and drink the entire contents.
Take on an empty stomach either a half hour before or two hours after a
meal.
May be mixed with water or juice to facilitate intake.
SIDE EFFECTS/WARNINGS
For oral use only.
Do not take this product if you have recently had a heart attack.
May not be suitable for children under 12 years of age,
pregnant or nursing women, or persons allergic fish (shark).
Consult a healthcare professional before use.
STORAGE
Keep Frozen. Do not thaw and refreeze.
Keep out of reach of children.
REFERENCES
Berbari P, et al. Antiangiogenic effects of the oral administration of
liquid cartilage extract in humans. J Surg Res. 1999 Nov;87(1):108-13Bilodeau
D, Bérubé J, Thibodeau A. A liquid extract with antiangiogenic and blood
modulating activities, for the support of first line cancer treatment.
Society of Integrative Oncology 1st International Conference, New
York, 2004Dupont E, et al. Antiangiogenic properties of a novel
shark cartilage extract: potential role in the treatment of psoriasis. J
Cutan Med Surg. 1998 Jan;2(3):146-52. Lee A, Langer R. Shark cartilage
contains inhibitors of tumor angiogenesis. Science. 1983 Sep
16;221(4616):1185-7.
Gonzalez RP, et al.
Shark cartilage as source of antiangiogenic compounds: from basic to
clinical research. Biol Pharm Bull. 2001 Oct;24(10):1097-101. Review.Thibodeau
A, Behr S. Liquid cartilage extract decreases symptoms of rheumatoid
arthritis. Townsend Letter for Doctors and Patients 2002. † -
Manufacturing process covered under US patent 5,618,925. Other US
patents on this liquid marine cartilage include 5,985,839, 6,025,334,
6,383,522. Additional patents pending.
*These statements have not been evaluated
by the
Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.